Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV DMT in Healthy Subjects
NCT05559931Phase 1Active, not recruiting
- Sponsor
- Algernon Pharmaceuticals Inc.
- Start
- Jan 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DMT in ischemic stroke (4 arms), sponsored by Algernon Pharmaceuticals Inc. Primary endpoints: Proportion of subjects with abnormal vital signs, Proportion of subjects with abnormal ECG readings and 7 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
DMT
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05559931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559931.